EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent advances in HER2-targeted inhibitors for cancer therapy

Wenjian Zhu, Xiaoyun Lu

Pharmaceutical Science Advances · 2026-12 · 4 · 100127

DOI: 10.1016/j.pscia.2026.100127 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Wenjian Zhu und 1 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecule…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changjiang Scholar Program, Ministry of Education, Jinan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2 (ErbB2), a ligand-independent HER family member, regulates cell growth, differentiation, and survival. Its overexpression, gene amplification, and activating mutations are oncogenic drivers in multiple malignancies. The past two decades have witnessed transformative advances in HER2-targeted therapeutics, exemplified by tyrosine kinase inhibitors (TKIs), including first-generation reversible pan-HER (e.g., lapatinib), second-generation covalent pan-HER (neratinib, pyrotinib), and novel selective HER2 inhibitors (tucatinib, sevabertinib, zongertinib). Nonetheless, the extensive molecular heterogeneity in HER2 activation (e.g., dimerization, amplification) and mutation profiles (e.g., L755S, exon 20 insertions), combined with tumor-type-specific pathogenic mechanisms, poses significant challenges to precision oncology in clinical practice. Currently, numerous promising inhibitors in preclinical and clinical development hold potential for providing more effective treatment options. This review comprehensively summarizes recent advances in HER2-targeted TKIs and their emergent resistance mechanisms, further analyzing strategies to both mitigate off-target toxicity and overcome resistance through rational design of selective HER2 inhibitors. Collectively, these insights provide a roadmap for developing next-generation precision therapies in HER2-driven cancers.

Schlagwörter

Stichwörter der Autor:innen

Clinical studyEx20ins mutationHER2 inhibitorsResistanceSelectivity

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International Cooperative Laborat…

Förderung

  • Changjiang Scholar Program, Ministry of Education
  • Jinan University

Zitieren

APA

Zhu, W., & Lu, X. (2026). Recent advances in HER2-targeted inhibitors for cancer therapy. Pharmaceutical Science Advances, 4, 100127. https://doi.org/10.1016/j.pscia.2026.100127

Vancouver

Zhu W, Lu X. Recent advances in HER2-targeted inhibitors for cancer therapy. Pharmaceutical Science Advances. 2026;4:100127. doi:10.1016/j.pscia.2026.100127

BibTeX
@article{Zhu2026,
  author = {Zhu, Wenjian and Lu, Xiaoyun},
  title = {Recent advances in HER2-targeted inhibitors for cancer therapy},
  journal = {Pharmaceutical Science Advances},
  year = {2026},
  volume = {4},
  pages = {100127},
  doi = {10.1016/j.pscia.2026.100127}
}
Kostenlos starten →